Cargando…

Next-generation sequencing identifies CDKN2A alterations as prognostic biomarkers in recurrent or metastatic head and neck squamous cell carcinoma predominantly receiving immune checkpoint inhibitors

BACKGROUND: This study aimed to identify potential biomarkers in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) and further probe the prognostic implications of CDKN2A mutations, particularly within a subset receiving immunotherapy. METHODS: In this retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xue, Liqiong, Tang, Wenbo, Zhou, Jiuli, Xue, Junli, Li, Qun, Ge, Xiaoxiao, Lin, Fengjuan, Zhao, Wei, Guo, Ye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627168/ https://www.ncbi.nlm.nih.gov/pubmed/37936609 http://dx.doi.org/10.3389/fonc.2023.1276009

Ejemplares similares

Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma
por: Qi, Xinmeng, et al.
Publicado: (2017)

Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma
por: Veigas, Florencia, et al.
Publicado: (2021)

Corrigendum to “PIPKIγ Regulates CCL2 Expression in Colorectal Cancer by Activating AKT-STAT3 Signaling”
por: Xue, JunLi, et al.
Publicado: (2020)

PIPKIγ Regulates CCL2 Expression in Colorectal Cancer by Activating AKT-STAT3 Signaling
por: Xue, JunLi, et al.
Publicado: (2019)

Cuproptosis-associated CDKN2A is targeted by plicamycin to regulate the microenvironment in patients with head and neck squamous cell carcinoma
por: Fan, Kaihui, et al.
Publicado: (2023)

Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma
por: Mei, Zi, et al.
Publicado: (2020)

No germline mutations in CDKN2A (p16) in patients with squamous cell cancer of the head and neck and second primary tumours
por: Jefferies, S, et al.
Publicado: (2001)

CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma
por: Chen, William S., et al.
Publicado: (2018)

Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
por: dos Santos, Lucas V., et al.
Publicado: (2021)

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
por: Oliva, M, et al.
Publicado: (2019)

Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma
por: Manukian, Gregor, et al.
Publicado: (2019)

Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
por: Park, Jong Chul, et al.
Publicado: (2022)

Identification of immune‐related lncRNA panel for predicting immune checkpoint blockade and prognosis in head and neck squamous cell carcinoma
por: Li, Qun, et al.
Publicado: (2022)

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma
por: Valero, Cristina, et al.
Publicado: (2023)

Therapeutic Targeting of MYC in Head and Neck Squamous Cell Carcinoma
por: Liu, Shuo, et al.
Publicado: (2022)

Individualized elective irradiation of the clinically node‐negative neck in definitive radiotherapy for head and neck squamous cell carcinoma
por: Kou, Jia, et al.
Publicado: (2021)

Immune Checkpoint Inhibition in Head and Neck Cancer
por: Forster, Martin David, et al.
Publicado: (2018)

Type Iγ phosphatidylinositol phosphate kinase promotes tumor growth by facilitating Warburg effect in colorectal cancer
por: Peng, Wei, et al.
Publicado: (2019)

HERG1A potassium channel is the predominant isoform in head and neck squamous cell carcinomas: evidence for regulation by epigenetic mechanisms
por: Menéndez, Sofía T., et al.
Publicado: (2016)

Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
por: Lechner, Axel, et al.
Publicado: (2017)

PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
por: Evrard, D., et al.
Publicado: (2020)

Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors
por: Liang, Xu, et al.
Publicado: (2022)

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Suzuki, Shinsuke, et al.
Publicado: (2021)

Prognostic Value of Inflammatory and Nutritional Biomarkers of Immune Checkpoint Inhibitor Treatment for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Sakai, Akihiro, et al.
Publicado: (2023)

Biomarkers in wound drainage fluids of head and neck squamous cell carcinoma patients receiving neck dissection: A pilot study
por: Gualtieri, Tommaso, et al.
Publicado: (2020)

Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma
por: Lim, Sun Min, et al.
Publicado: (2019)

The Identification of Stemness-Related Genes in the Risk of Head and Neck Squamous Cell Carcinoma
por: Feng, Guanying, et al.
Publicado: (2021)

Primary histiocytic sarcoma arising in the head and neck with predominant spindle cell component
por: Alexiev, Borislav A, et al.
Publicado: (2007)

The Prognostic Value of TP53 Alteration in Patients with Head and Neck Squamous Cell Carcinoma Receiving Immunotherapy
por: Jiang, Chao, et al.
Publicado: (2022)

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
por: Cavalieri, Stefano, et al.
Publicado: (2021)

Immune‐checkpoint molecules on regulatory T‐cells as a potential therapeutic target in head and neck squamous cell cancers
por: Suzuki, Susumu, et al.
Publicado: (2020)

Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab
por: Tanoue, Kenro, et al.
Publicado: (2021)

Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
por: Arribas, Lorena, et al.
Publicado: (2021)

Osteopontin Levels in Patients with Squamous Metastatic Head and Neck Cancer
por: Maleš, Josip, et al.
Publicado: (2021)

Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Hsieh, Ronan W., et al.
Publicado: (2021)

Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis
por: Jia, Yi-Qun, et al.
Publicado: (2019)

Socioeconomic factors and survival in patients with non‐metastatic head and neck squamous cell carcinoma
por: Xu, Cheng, et al.
Publicado: (2017)

Overexpression of TRIM24 Stimulates Proliferation and Glucose Metabolism of Head and Neck Squamous Cell Carcinoma
por: Wang, Hongming, et al.
Publicado: (2018)

Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy
por: Porceddu, Sandro V., et al.
Publicado: (2020)

Bayesian Networks to Support Decision-Making for Immune-Checkpoint Blockade in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
por: Huehn, Marius, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tur3k3fgrrj2bip9si99s1fd5t